Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013 (2013), Article ID 498485, 8 pages
Research Article

Liposomes-in-Hydrogel Delivery System with Mupirocin: In Vitro Antibiofilm Studies and In Vivo Evaluation in Mice Burn Model

1Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Universitetsveien 57, 9037 Tromsø, Norway
2Vascular Biology Research Group, Department of Medical Biology, University of Tromsø, Universitetsveien 57, 9037 Tromsø, Norway
3Pharmaceutical Sciences, Department of Biosciences, Abo Akademi University, Artillerigatan 6A, 20520 Åbo, Finland
4Division of Pharmaceutical Biology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Finland

Received 3 October 2013; Accepted 11 November 2013

Academic Editor: Jyrki Heinämäki

Copyright © 2013 Julia Hurler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Previously, we have proposed mupirocin-in-liposomes-in-hydrogel delivery system as advanced delivery system with the potential in treatment of burns. In the current studies, we evaluated the system for its cytotoxicity, ability to prevent biofilm formation, act on the mature biofilms, and finally determined its potential as wound treatment in in vivo mice burn model. The system was found to be nontoxic against HaCaT cells, that is, keratinocytes. It was safe for use and exhibited antibiofilm activity against S. aureus biofilms, although the activity was more significant against planktonic bacteria and prior to biofilm formation than against mature biofilms as shown in the resazurin and the crystal violet assays. An in vivo mice burn model was used to evaluate the biological potential of the system and the healing of burns observed over 28 days. The in vivo data suggest that the delivery system enhances wound healing and is equally potent as the marketed product of mupirocin. Histological examination showed no difference in the quality of the healed scar tissue, whereas the healing time for the new delivery system was shorter as compared to the marketed product. Further animal studies and development of more sophisticated in vivo model are needed for complete evaluation.